SI2021002T1 - Farmacevtski sestavek, ki vsebuje olmesartan medoksomil - Google Patents

Farmacevtski sestavek, ki vsebuje olmesartan medoksomil

Info

Publication number
SI2021002T1
SI2021002T1 SI200731003T SI200731003T SI2021002T1 SI 2021002 T1 SI2021002 T1 SI 2021002T1 SI 200731003 T SI200731003 T SI 200731003T SI 200731003 T SI200731003 T SI 200731003T SI 2021002 T1 SI2021002 T1 SI 2021002T1
Authority
SI
Slovenia
Prior art keywords
olmesartan medoxomil
pharmaceutical composition
medoxomil
olmesartan
subjecting
Prior art date
Application number
SI200731003T
Other languages
English (en)
Inventor
Matej Avanzo
Peterka Tanja Rozman
Igor Legen
Original Assignee
Lek Pharmaceuticals D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals D.D. filed Critical Lek Pharmaceuticals D.D.
Publication of SI2021002T1 publication Critical patent/SI2021002T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200731003T 2006-05-04 2007-05-02 Farmacevtski sestavek, ki vsebuje olmesartan medoksomil SI2021002T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06009223A EP1891952B1 (en) 2006-05-04 2006-05-04 Pharmaceutical composition of olmesartan medoxomil
EP07724794A EP2021002B1 (en) 2006-05-04 2007-05-02 Pharmaceutical composition comprising olmesartan medoxomil
PCT/EP2007/003868 WO2007128478A2 (en) 2006-05-04 2007-05-02 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
SI2021002T1 true SI2021002T1 (sl) 2012-10-30

Family

ID=37076372

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200631227T SI1891952T1 (sl) 2006-05-04 2006-05-04 Farmacevtski sestavek, ki vsebuje olmesartan medoksomil
SI200731003T SI2021002T1 (sl) 2006-05-04 2007-05-02 Farmacevtski sestavek, ki vsebuje olmesartan medoksomil

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200631227T SI1891952T1 (sl) 2006-05-04 2006-05-04 Farmacevtski sestavek, ki vsebuje olmesartan medoksomil

Country Status (8)

Country Link
US (1) US9707178B2 (sl)
EP (2) EP1891952B1 (sl)
AT (1) ATE526963T1 (sl)
CA (1) CA2651138C (sl)
ES (1) ES2388880T3 (sl)
PL (1) PL2021002T3 (sl)
SI (2) SI1891952T1 (sl)
WO (1) WO2007128478A2 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101628028B1 (ko) 2006-06-27 2016-06-08 다이이찌 산쿄 가부시키가이샤 압축 제제
EP2228066A1 (en) * 2009-03-03 2010-09-15 LEK Pharmaceuticals d.d. Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties
WO2011045760A2 (en) * 2009-10-13 2011-04-21 Ranbaxy Laboratories Limited Micronized olmesartan medoxomil compositions
WO2011083112A2 (en) 2010-01-05 2011-07-14 Ratiopharm Gmbh Solid oral dosage form containing olmesartan medoxomil
TR201005867A1 (tr) 2010-07-16 2012-02-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Olmesartan farmasötik bileşimleri.
JP5705562B2 (ja) * 2011-01-25 2015-04-22 沢井製薬株式会社 カンデサルタンシレキセチル含有錠剤及びその製造方法
WO2014002011A1 (en) * 2012-06-26 2014-01-03 Micro Labs Limited Micronized particles of olmesartan medoxomil and pharmaceutical composition thereof
WO2014188729A1 (ja) * 2013-05-24 2014-11-27 持田製薬株式会社 経口用組成物
JP6653116B2 (ja) * 2014-08-27 2020-02-26 日本ケミファ株式会社 オルメサルタンのプロドラッグ製剤
CN107998097B (zh) * 2018-01-17 2018-08-31 扬子江药业集团上海海尼药业有限公司 一种含奥美沙坦酯的片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
US6555139B2 (en) * 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6833381B2 (en) * 2000-02-18 2004-12-21 Takeda Chemical Industries, Ltd. TNF-α inhibitors
ES2262689T3 (es) * 2000-11-21 2006-12-01 Sankyo Company, Limited Composicion que contiene un antagonista del receptor de angiotensina ii y un diuretico y su uso para el tratamiento de la hipertension.
EP1604664A4 (en) * 2003-01-31 2006-12-27 Sankyo Co MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
EP1776095A1 (en) * 2004-06-23 2007-04-25 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
US20070054948A1 (en) * 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
WO2006029057A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Purification of olmesartan medoxomil
AU2005298986A1 (en) * 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
US20060281800A1 (en) * 2005-04-12 2006-12-14 Glenmark Pharmaceuticals Limited Polymorphic form of olmesartan and process for its preparation
CA2616466A1 (en) * 2005-07-29 2007-02-15 Krka Process for the preparation of olmesartan medoxomil

Also Published As

Publication number Publication date
EP1891952A1 (en) 2008-02-27
CA2651138A1 (en) 2007-11-15
EP2021002B1 (en) 2012-05-30
ES2388880T3 (es) 2012-10-19
WO2007128478A3 (en) 2008-02-07
SI1891952T1 (sl) 2012-02-29
WO2007128478A2 (en) 2007-11-15
EP1891952B1 (en) 2011-10-05
EP2021002A2 (en) 2009-02-11
CA2651138C (en) 2016-02-16
US20090238871A1 (en) 2009-09-24
PL2021002T3 (pl) 2012-11-30
US9707178B2 (en) 2017-07-18
ATE526963T1 (de) 2011-10-15

Similar Documents

Publication Publication Date Title
SI2021002T1 (sl) Farmacevtski sestavek, ki vsebuje olmesartan medoksomil
BR112012011328A2 (pt) inibidores de akt
MX2010004493A (es) Compuestos de tropano.
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
UA102534C2 (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]-dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
TW200611897A (en) Organic compounds
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
WO2008098978A3 (en) Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
NO20085317L (no) Imidazoazepinonforbindelser
WO2007130821A3 (en) Mglur5 modulators ii
WO2010047592A3 (en) Preservation mixture and use thereof
WO2009062874A3 (en) Benzimidazole derivatives and their use as fxr agonists
MX2009008221A (es) Antagonista de receptor de cromeno s1p1.
WO2007095021A3 (en) Novel compounds
WO2011047055A8 (en) Novel mek inhibitors, useful in the treatment of diseases
WO2008098143A3 (en) Antimicrobial compounds and methods of use
DE602007005387D1 (de) Ptors
WO2010059639A3 (en) Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2007145563A8 (en) Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor